Michael E Ernst1,2, Eric J MacLaughlin3. 1. Department of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa, Iowa City, IA, USA. michael-ernst@uiowa.edu. 2. Department of Family Medicine,Carver College of Medicine, The University of Iowa, 01291-A PFP, 200 Hawkins Dr, Iowa City, IA, 52242, USA. michael-ernst@uiowa.edu. 3. Department of Pharmacy Practice, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Abstract
PURPOSE OF REVIEW: Use of antihypertensives in older adults can be complicated by the potential for undesired effects on comorbidities, adverse effects of the drugs, and overall medication burden. The purpose of this two-part review is to discuss contemporary issues encountered in the management of hypertension in aged individuals, with a particular focus on considerations for the individualization of treatment. In Part 2, we discuss the individualized approach to treating hypertension in the elderly. RECENT FINDINGS: Achieving lower blood pressure goals in older adults has the potential to increase risks for complications such as hypotension and acute renal insufficiency, especially in those less healthy. Because elderly exhibit many different phenotypes, a one-size-fits-all approach to treatment goals and choice of antihypertensives is problematic. Many areas of uncertainty remain, including what the optimal goal blood pressure should be in frail or institutionalized elderly, whether there is an upper age limit for treatment initiation where benefits and risks overlap, and when de-escalation of antihypertensives should be considered. Hypertension is a major modifiable risk factor, and the benefits of treatment in lowering cardiovascular events are realized for most individuals, even at advanced ages. Areas of uncertainty in the management of hypertension in this group mandate a cautious, individualized approach to treatment which relies on careful assessment of biologic or phenotypic age, rather than chronologic age alone.
PURPOSE OF REVIEW: Use of antihypertensives in older adults can be complicated by the potential for undesired effects on comorbidities, adverse effects of the drugs, and overall medication burden. The purpose of this two-part review is to discuss contemporary issues encountered in the management of hypertension in aged individuals, with a particular focus on considerations for the individualization of treatment. In Part 2, we discuss the individualized approach to treating hypertension in the elderly. RECENT FINDINGS: Achieving lower blood pressure goals in older adults has the potential to increase risks for complications such as hypotension and acute renal insufficiency, especially in those less healthy. Because elderly exhibit many different phenotypes, a one-size-fits-all approach to treatment goals and choice of antihypertensives is problematic. Many areas of uncertainty remain, including what the optimal goal blood pressure should be in frail or institutionalized elderly, whether there is an upper age limit for treatment initiation where benefits and risks overlap, and when de-escalation of antihypertensives should be considered. Hypertension is a major modifiable risk factor, and the benefits of treatment in lowering cardiovascular events are realized for most individuals, even at advanced ages. Areas of uncertainty in the management of hypertension in this group mandate a cautious, individualized approach to treatment which relies on careful assessment of biologic or phenotypic age, rather than chronologic age alone.
Authors: M J Brown; J K Cruickshank; A F Dominiczak; G A MacGregor; N R Poulter; G I Russell; S Thom; B Williams Journal: J Hum Hypertens Date: 2003-02 Impact factor: 3.012
Authors: Dena Ettehad; Connor A Emdin; Amit Kiran; Simon G Anderson; Thomas Callender; Jonathan Emberson; John Chalmers; Anthony Rodgers; Kazem Rahimi Journal: Lancet Date: 2015-12-24 Impact factor: 79.321
Authors: Michelle C Odden; Carmen A Peralta; Dan R Berlowitz; Karen C Johnson; Jeffrey Whittle; Dalane W Kitzman; Srinivasan Beddhu; John W Nord; Vasilios Papademetriou; Jeff D Williamson; Nicholas M Pajewski Journal: JAMA Intern Med Date: 2017-04-01 Impact factor: 21.873
Authors: Jeff D Williamson; Mark A Supiano; William B Applegate; Dan R Berlowitz; Ruth C Campbell; Glenn M Chertow; Larry J Fine; William E Haley; Amret T Hawfield; Joachim H Ix; Dalane W Kitzman; John B Kostis; Marie A Krousel-Wood; Lenore J Launer; Suzanne Oparil; Carlos J Rodriguez; Christianne L Roumie; Ronald I Shorr; Kaycee M Sink; Virginia G Wadley; Paul K Whelton; Jeffrey Whittle; Nancy F Woolard; Jackson T Wright; Nicholas M Pajewski Journal: JAMA Date: 2016-06-28 Impact factor: 56.272
Authors: Giulia Ogliari; Rudi G J Westendorp; Majon Muller; Daniela Mari; Erminio Torresani; Irene Felicetta; Tiziano Lucchi; Paolo D Rossi; Behnam Sabayan; Anton J M de Craen Journal: Age Ageing Date: 2015-11 Impact factor: 10.668
Authors: Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright Journal: Hypertension Date: 2017-11-13 Impact factor: 9.897